- Home
- XFOR vs CHN Comparison
XFOR vs CHN Comparison
Compare XFOR & CHN Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XFOR
- CHN
- Stock Information
- Founded
- XFOR 2014
- CHN 1992
- Country
- XFOR United States
- CHN United States
- Employees
- XFOR N/A
- CHN N/A
- Industry
- XFOR Biotechnology: Biological Products (No Diagnostic Substances)
- CHN Investment Managers
- Sector
- XFOR Health Care
- CHN Finance
- Exchange
- XFOR Nasdaq
- CHN Nasdaq
- Market Cap
- XFOR 118.4M
- CHN 128.4M
- IPO Year
- XFOR N/A
- CHN N/A
- Fundamental
- Price
- XFOR $2.68
- CHN $13.07
- Analyst Decision
- XFOR Strong Buy
- CHN
- Analyst Count
- XFOR 3
- CHN 0
- Target Price
- XFOR $72.33
- CHN N/A
- AVG Volume (30 Days)
- XFOR 357.1K
- CHN 31.8K
- Earning Date
- XFOR 08-07-2025
- CHN 01-01-0001
- Dividend Yield
- XFOR N/A
- CHN 0.19%
- EPS Growth
- XFOR N/A
- CHN N/A
- EPS
- XFOR 2.16
- CHN N/A
- Revenue
- XFOR $31,364,000.00
- CHN N/A
- Revenue This Year
- XFOR $1,106.53
- CHN N/A
- Revenue Next Year
- XFOR N/A
- CHN N/A
- P/E Ratio
- XFOR $1.23
- CHN N/A
- Revenue Growth
- XFOR N/A
- CHN N/A
- 52 Week Low
- XFOR $2.62
- CHN $9.00
- 52 Week High
- XFOR $31.20
- CHN $12.98
- Technical
- Relative Strength Index (RSI)
- XFOR 36.75
- CHN 58.19
- Support Level
- XFOR $2.62
- CHN $13.13
- Resistance Level
- XFOR $2.98
- CHN $13.33
- Average True Range (ATR)
- XFOR 0.38
- CHN 0.17
- MACD
- XFOR -0.02
- CHN 0.01
- Stochastic Oscillator
- XFOR 9.68
- CHN 75.70
About XFOR X4 Pharmaceuticals Inc.
X4 Pharmaceuticals Inc is a late-stage clinical biopharmaceutical company engaged in the research and development of novel therapeutics for the treatment of rare diseases and those with limited treatment options, with a focus on conditions resulting from dysfunction of the immune system. The Company's lead clinical candidate is mavorixafor, a small molecule antagonist of the chemokine receptor CXCR4 that is being developed as an oral, once-daily therapy. It has the ability to increase the mobilization of mature, functional white blood cells from the bone marrow into the bloodstream. It also has two pre-clinical candidates X4P-003 and X4P-002 which are CXCR4 antagonists with different properties.
About CHN China Fund Inc. (The)
CHINA FUND INC is a non-diversified, closed-end management investment company. Its investment objective is a long-term capital appreciation which it seeks to achieve by investing in equity securities with trading in China and outside China. It invests in various industries such as Insurance, Entertainment, Machinery, Electrical Equipment, Beverages, Hotels, Restaurants, and Leisure among others.